Francisco Partners, the parent company had acquired Aesynt in October 2013. Aesynt provides enterprise software which involve medication logistics management software, automated procurement and order management, and reporting & analytics for inventory management and medication utilization. It also provides full suite of automated and semi-automated solutions for the IV room; central pharmacy solutions; and point of care solutions.
“Aesynt brings distinct capacities in dispensing systems, central pharmacy robotics, IV robotics and analytics,” said Randall Lipps, CEO of Omnicell.
“We expect that as a combined entity we can accelerate innovation in the marketplace by leveraging the combined strengths of the Aesynt and Omnicell teams. Choice, innovation and value make this a great acquisition for Omnicell and our customers.”
The combined company would support approximately 4,000 acute care facilities worldwide, have annual revenues of over $650 million and have approximately 2,200 employees.
The completion of the transaction is subject to Hart-Scott-Rodino review and the satisfaction of other customary closing conditions, and is expected to close in 2016. Aesynt recorded approximately $182 million of revenue and approximately $20 million of adjusted EBITDA (unaudited) in the last twelve months ended June 30, 2015.
